combination low dose tissue type-plasminogen activator plus annexin a2 for improving thrombolytic stroke therapy
Clicks: 200
ID: 259771
2015
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
30.0
/100
199 views
17 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Risk of hemorrhagic transformation, incomplete reperfusion, neurotoxicity and a short treatment time window comprise major challenges for tissue plasminogen activator (tPA) thrombolytic stroke therapy. Improving tPA therapy has become one of the highest priorities in the stroke field. This mini review article focuses on our recent efforts aimed at evaluating a novel combination approach of low-dose tPA plus recombinant annexin A2 (rA2, a tPA and plasminogen co-receptor), that might enhance tPA thrombolytic efficacy, while reducing its associated complications related to intracerebral hemorrhagic (ICH) transformation. Results of our experimental studies using a focal embolic stroke model in rats support the feasibility of the combination approach and suggest the potential for successful clinical translation.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (112 words).
Try re-searching for a better abstract.
| Reference Key |
ejiang2015frontierscombination
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Yinghua eJiang;Yinghua eJiang;Xiang eFan;Xiang eFan;Zhanyang eYu;Zhengbu eLiao;Zhengbu eLiao;Xiao-Shu eWang;Xiao-Shu eWang;Klaus evan leyen;Xiaochuan eSun;Eng H Lo;Xiaoying eWang |
| Journal | macromolecular bioscience |
| Year | 2015 |
| DOI |
10.3389/fncel.2015.00397
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.